Education
About Us
Working with TipRanks
Follow Us
Alcon Inc (CH:ALC)
:ALC
Top Page
Alcon
(ALC)
Select Model
Select Model
Rating:72Outperform
Price Target:
CHF74.00
▲(10.84% Upside)
Action:ReiteratedDate:02/28/26
The score is driven primarily by solid fundamentals (steady growth, healthy profitability, improving free cash flow, and manageable leverage) and supportive technical momentum (price above major moving averages with positive MACD). These positives are tempered by an expensive valuation (high P/E with low yield) and near-term execution/margin risks noted on the earnings call, including tariff impacts and competitive pressures.
Positive Factors
Strong free cash flow & capital returns
Alcon's materially improved free cash flow (F F C of ~$1.7B in 2025) and disciplined capital returns (>$800M returned) indicate durable internal funding for R&D, product rollouts and shareholder distributions. Persistent FCF supports investment without forcing excess leverage, enhancing long-term financial flexibility.
Broad, high-impact product pipeline
A pipeline of surgical and vision innovations (Unity equipment, PanOptix Pro, TruPlus, Total30, Truqtra traction) provides sustainable drivers of installed base growth, consumable attach rates and share gains. Multi-year product cadence supports recurring revenues and strengthens competitive moats in core eye‑care markets.
Manageable leverage and sizable asset base
Relatively low net leverage and an expanded asset base (~$31.5B) give Alcon balance sheet capacity to fund capital expenditures, M&A or buybacks while absorbing cyclical shocks. This structural financial strength supports strategic investments and underpins resilience through multi-quarter market fluctuations.
Negative Factors
Tariff-related margin headwinds
Ongoing retaliatory tariffs are a structural cost pressure that directly reduces gross margins and increases unit costs. With management assuming a ~15% tariff rate into 2026, this weighs on sustainable profitability and creates recurring modeling uncertainty for margins and pricing strategies across geographies.
Recent margin compression and operating softness
Material year‑over‑year margin deterioration reflects higher S&M behind launches, increased R&D and tariff impacts. Persistently pressured operating margins reduce earnings leverage from revenue growth and make multi‑period margin recovery dependent on execution of efficiency programs and favorable mix shifts.
Inconsistent cash conversion
Although FCF improved, cash conversion below net income signals working‑capital timing and quality variability. Inconsistent conversion can constrain free cash availability in weaker revenue periods and complicate planning for capex, R&D funding and steady shareholder returns over multiple quarters.
Alcon (ALC) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF33.41B
Dividend Yield0.44%
Average Volume (3M)1.17M
Price to Earnings (P/E)40.5
Beta (1Y)0.99
Revenue Growth0.39%
EPS Growth-12.46%
CountryCH
Employees25,599
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.60
Shares Outstanding499,700,000
10 Day Avg. Volume1,341,371
30 Day Avg. Volume1,171,640
Financial Highlights & Ratios
PEG Ratio39.50
Price to Book (P/B)1.79
Price to Sales (P/S)3.61
P/FCF Ratio21.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF72.88Price Target Upside9.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)2.66
Revenue Forecast (FY)CHF8.62B
Alcon Business Overview & Revenue Model
Company DescriptionAlcon Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantables products, including AcrySof IQ IOLs products include monofocal IOLs and advanced technology IOLs under the PanOptix and ReSTOR brands for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers under the TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux brands. The company was formerly known as Alcon Universal S.A. and changed the name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
How the Company Makes MoneyAlcon generates revenue through multiple streams, primarily from the sale of surgical products and vision care products. The Surgical segment includes revenue from cataract surgery devices, which are critical for treating cataracts, and refractive surgery devices used for vision correction procedures. The Vision Care segment derives income from the sale of contact lenses and lens care products, catering to both daily and extended wear needs. Alcon's revenue model is bolstered by strong relationships with healthcare professionals, hospitals, and clinics, which facilitate widespread distribution of its products. Additionally, the company invests in research and development to innovate new products and improve existing offerings, thereby enhancing its market competitiveness. Strategic partnerships with healthcare providers and participation in global eye care initiatives further contribute to its earnings.
Alcon Earnings Call Summary
Earnings Call Date:Feb 24, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 19, 2026
Earnings Call Sentiment Positive
The call presents a predominantly positive underlying operational story: broad-based top-line growth across Surgical, Vision Care, and Ocular Health, successful new-product introductions (Unity, PanOptix Pro, Truqtra, Total30 expansions), strong free cash flow and accelerated shareholder returns, and explicit guidance for margin improvement and EPS growth in 2026. Offsetting these positives are notable near-term headwinds — tariff-related charges, margin compression in the quarter, an increasingly competitive IOL environment (with China and some international softness), and execution/phasing uncertainty as equipment and new-product ramps continue. On balance, the highlights (strong revenue growth, successful launches, robust cash generation, and disciplined capital allocation plus a clear plan to drive margins) outweigh the lowlights, though management is appropriately cautious on guidance and market visibility.Q4-2025 Updates
Positive Updates
Strong Overall Revenue Growth
Q4 sales of $2.7 billion, up 7% versus prior year; full-year momentum with management exiting 2025 on a stronger rate.
Surgical & Equipment Momentum (Unity)
Surgical revenue $1.5 billion, up 6% YoY; Equipment sales $77 million, up 18% driven by Unity VCS/CS launches and strong installation demand for Unity VCS (introduced mid‑2025).
Vision Care and Contact Lens Performance
Vision Care sales $1.2 billion, up 7% YoY; Contact Lens sales $683 million, up 4% (growth driven by product innovation and price), notable share gains in reusables and daily SiHy in Q4.
Ocular Health and Truqtra Launch Success
Ocular Health sales $474 million, up 12% YoY; Truqtra surpassed ~84,000 prescriptions and achieved ~3% U.S. market share within ~5 months of launch, with >33% commercial lives covered and high refill rates—management expects it to be a meaningful 2026 growth driver.
Product Pipeline and Notable Launches
Multiple high-impact launches and pipeline items: Unity VCS award recognition and broad roll-out; PanOptix Pro strong U.S. adoption (rolling out in Japan/Australia); TruPlus (FDA PMA) launching soon; Vivity upgrade planned for 2027; Total30 Multifocal for Astigmatism launched; Valeda showing encouraging adoption and reimbursement progress (6 of 7 MACs).
Strong Cash Generation & Shareholder Returns
Generated $1.7 billion free cash flow in 2025 (vs $1.6B in 2024); free cash flow was 114% of core net income; returned $848 million to shareholders in 2025 ($682M repurchases, $166M dividends) and completed $750M repurchase program ahead of schedule.
Prudent 2026 Guidance & Margin Improvement Plan
2026 outlook: sales growth guidance 5%–7%; market assumption 3%–4%; core diluted EPS growth guidance 9%–12%; core operating margin expected to expand ~70–170 bps driven by SG&A leverage, R&D at ~9% of sales, and announced efficiency program targeting $100M annualized savings (≈$50M recognized in 2026) at an estimated $150M cost.
Negative Updates
Gross and Operating Margin Pressure
Q4 core gross margin 62.5%, down 50 basis points YoY; core operating margin 19.0%, down 160 basis points YoY — driven by tariff-related costs, increased sales & marketing investments behind new launches, and higher R&D spend.
Tariff-Related Headwinds
Incurred $91 million of tariff-related charges in 2025 (with $67 million recognized in cost of sales); 2026 outlook assumes ~15% average tariff rate for U.S. imports, representing an ongoing margin headwind and modeling uncertainty.
Increasingly Competitive IOL Market and International Softness
Management noted an increasingly competitive IOL market; Implantables were $474 million in Q4, up only 2% YoY. International softness (Japan, parts of Asia) and China-specific issues (hospital VBP budget constraints leading to lower AT‑IOL adoption and shifts toward bifocal use) weighed on performance.
Equipment Ramp and Margin Mix Effects
Equipment acceleration (Unity) benefits growth but equipment-heavy mix and ramping can press overall gross margins (equipment has lower immediate consumable attach compared with mature installed base).
Tough Comparables and Legacy Product Declines
Contact Lens faced tough comps (double-digit growth in prior year) and declines in legacy products where promotional activity was reduced; management noted some legacy product declines as they de-emphasize lower-margin SKUs.
Execution & Market Visibility Risks
Management characterized 2025 as a softer market year and kept 2026 guidance conservative given remaining uncertainty in market normalization, phasing of new product ramps, and potential retaliatory tariff changes; visibility to normalized demand remains imperfect.
Near-term Restructuring and Transformation Costs
Efficiency program to realize $100M annualized savings will incur approximately $150M of costs (with ~ $50M of savings realized in 2026), creating near-term cash/earnings drag while delivering longer-term savings.
Company Guidance
Alcon’s 2026 guidance assumes aggregate eye‑care market growth of 3–4%, January exchange rates holding, and an average U.S. import tariff rate of ~15% (retaliatory tariffs unchanged); management expects 2026 sales growth of 5–7% (constant currency), with sales relatively level‑loaded and the second half more profitable than the first. They expect 2026 core gross margin to be broadly similar to 2025 (Q4 core gross margin was 62.5%), R&D of ~9% of sales, and have announced efficiency measures targeting $100M of annualized run‑rate savings (about $50M realized in 2026 at a one‑time cost of ~$150M) that should drive full‑year core operating‑margin expansion of ~70–170 basis points (Q4 core operating margin was 19%). On the bottom line they expect core diluted EPS growth of 9–12% (constant currency); 2025 free cash flow was $1.7B (114% of core net income), 2025 tariff‑related charges were $91M ($67M in cost of sales), interest expense in Q4 was $53M, and capital returns in 2025 totaled $848M (share repurchases $682M, dividends $166M) with the $750M repurchase program completed in January and a proposed dividend of $0.28/share.Alcon Financial Statement Overview
Summary
Steady 2023–2025 revenue growth with healthy gross margin (~55%) and improving free cash flow, supported by manageable leverage. Offsets include modest ROE (~4–5%), some 2025 margin softening versus 2024, and uneven cash conversion (operating cash flow and FCF below net income in 2025 per the provided statements).Income Statement
Revenue has grown steadily from 2023–2025 (to ~10.9B in 2025) with positive growth in each of the last three annual periods, pointing to improving demand and execution. Profitability has strengthened materially versus 2020, with 2025 gross margin ~55% and net margin ~9%; however, net margin peaked in 2023–2024 (~10%) and dipped in 2025, and operating profitability also eased in 2025 versus 2024. Overall, solid growth and healthy margins, but with some recent margin compression to monitor.78
Positive
Balance Sheet
Leverage appears manageable: debt is ~5.7B against equity of ~22.0B in 2025, keeping debt relative to equity around ~0.26 and fairly stable over time. Asset base has expanded (to ~31.5B in 2025), supporting scale and resilience. The main weakness is modest shareholder returns (return on equity ~4–5% in 2023–2025), suggesting profitability is good but not yet translating into high returns on the capital base.74
Positive
Cash Flow
Cash generation improved meaningfully: free cash flow rose from ~0.54B (2023) to ~1.81B (2025), with strong 2025 growth. That said, cash conversion is not consistently strong—2025 operating cash flow is below net income (coverage ~0.78), and free cash flow is also below net income (~0.76), indicating working-capital or cash timing headwinds. Overall trending better with stronger free cash flow, but quality/consistency of conversion is a key watch item.70
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 10.90B | 9.91B | 9.46B | 8.72B | 8.29B |
| Gross Profit | 6.02B | 5.51B | 5.25B | 4.75B | 4.65B |
| EBITDA | 2.78B | 2.68B | 2.24B | 1.72B | 1.76B |
| Net Income | 1.03B | 1.02B | 974.00M | 335.00M | 376.00M |
Balance Sheet | |||||
| Total Assets | 31.53B | 30.35B | 29.61B | 29.21B | 28.00B |
| Cash, Cash Equivalents and Short-Term Investments | 1.61B | 1.83B | 1.10B | 980.00M | 1.58B |
| Total Debt | 5.67B | 5.14B | 5.13B | 5.07B | 4.48B |
| Total Liabilities | 9.51B | 8.79B | 8.99B | 9.53B | 8.74B |
| Stockholders Equity | 22.02B | 21.55B | 20.62B | 19.68B | 19.26B |
Cash Flow | |||||
| Free Cash Flow | 1.81B | 1.41B | 537.00M | 472.00M | 165.00M |
| Operating Cash Flow | 2.38B | 2.08B | 1.39B | 1.22B | 1.34B |
| Investing Cash Flow | -1.44B | -1.17B | -1.09B | -1.86B | -1.20B |
| Financing Cash Flow | -1.14B | -322.00M | -211.00M | -8.00M | -123.00M |
Alcon Technical Analysis
Positive
66.76
Price Trends
62.98
Positive
62.13
Positive
65.28
Positive
Market Momentum
0.82
Negative
66.84
Neutral
84.92
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:ALC, the sentiment is Positive. The current price of 66.76 is above the 20-day moving average (MA) of 62.32, above the 50-day MA of 62.98, and above the 200-day MA of 65.28, indicating a bullish trend. The MACD of 0.82 indicates Negative momentum. The RSI at 66.84 is Neutral, neither overbought nor oversold. The STOCH value of 84.92 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:ALC.
Alcon Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | CHF248.37B | 21.79 | ― | 3.18% | 7.62% | -18.33% | |
77 Outperform | CHF293.78B | 22.68 | 31.98% | 2.94% | 4.77% | -11.07% | |
72 Outperform | CHF33.41B | 40.52 | 4.50% | 0.44% | 0.39% | -12.46% | |
70 Outperform | CHF34.26B | 105.59 | ― | 0.09% | 6.22% | ― | |
68 Neutral | CHF11.62B | 23.13 | ― | 2.14% | 3.79% | -7.84% | |
66 Neutral | CHF14.76B | 41.48 | ― | 1.02% | 4.49% | 45.08% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
CH:ALC
Alcon
66.86
-16.25
-19.55%
CH:ROG
Roche Holding AG
367.00
77.38
26.72%
CH:NOVN
Novartis AG
130.50
36.21
38.40%
CH:STMN
Straumann Holding AG
92.60
-28.23
-23.36%
CH:SOON
Sonova Holding AG
201.90
-82.16
-28.92%
CH:GALD
Galderma Group AG
145.90
36.14
32.93%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.